Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company whose news flow is centered on the development of therapies for oncology, dermatology, neurodegenerative disease, metabolic disease, and inflammatory conditions. Company updates frequently highlight progress across its pipeline, including HT-001 for cancer-therapy–related skin toxicities, HT-KIT for KIT-driven cancers and mast-cell diseases, HT-ALZ for Alzheimer’s disease, and a GDNF-based metabolic program targeting obesity and fatty liver disease.
News releases from Hoth often cover clinical milestones such as Phase 2 trial activity for HT-001 in EGFR-inhibitor–associated rash, first-in-human study preparations, and regulatory developments in the European Union and the United States. The company also reports on FDA designations, including Orphan Drug Designation for HT-KIT, and on IND-enabling progress and preclinical data in systemic mastocytosis and GIST models.
Investors and followers of HOTH stock can also expect updates on intellectual property expansion, including provisional patent filings and international patent protection related to HT-001 and other programs. Hoth regularly announces collaborations and research partnerships, such as its VA-backed GDNF study at the Atlanta VA Medical Center and participation in NVIDIA’s AI-focused programs to support computational biology and predictive modeling.
This news page aggregates Hoth Therapeutics’ press releases and related coverage, providing a single place to review developments in its clinical trials, regulatory interactions, AI-enabled research initiatives, conference presentations, and corporate communications. Readers interested in the evolution of HOTH’s pipeline and regulatory strategy can use this feed to monitor ongoing announcements and historical updates.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has initiated a preclinical study for its drug candidate HT-ALZ targeting Alzheimer's disease. The study aims to assess the impact of HT-ALZ on behavioral and pathological markers of the disease, including improvements in learning and memory in an animal model. Additionally, it will evaluate the drug's effect on non-spatial memory and the role of NK-1R blocking. This research follows a Scientific Research Agreement established in June, aiming to advance innovative therapeutic solutions.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced positive results for its HT-003 acne therapeutic assets. The study revealed that HT-003 significantly reduces the expression of toll-like receptor 2 (TLR2) and various cytokines linked to acne and other inflammatory skin conditions. The research involved treating mouse skin with RAMBA before inducing acne-like inflammation, demonstrating the efficacy of HT-003 in inhibiting inflammatory markers. Dr. Jonathan Zippin noted the promising potential of HT-003 for treating and preventing acne, with further applications explored for inflammatory bowel disorders.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced positive interim safety results from Cohort 1 of their first human trial for BioLexa, aimed at treating atopic dermatitis. A total of ten subjects received the treatment twice daily for 14 days, with no serious adverse events reported. CEO Robb Knie highlighted this milestone as the company prepares for Cohort 2 enrollment later in the year. BioLexa is designed to combat bacterial biofilms that complicate infections, offering a novel mechanism for treating conditions associated with these biofilms.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced a Sponsored Research Agreement with Washington University to advance the development of HT-ALZ, aimed at treating symptoms associated with Alzheimer's disease. The research will be led by Dr. John Cirrito and Dr. Carla Yuede, focusing on amyloid-beta metabolism's role in Alzheimer's. Hoth's CEO emphasized the goal of developing innovative therapeutics to meet patient needs and enhance shareholder value.
Hoth Therapeutics (NASDAQ: HOTH) announced positive preclinical trial results for its investigational therapy HT-KIT, aimed at treating mast cell-derived cancers and anaphylaxis. Conducted in humanized mast cell neoplasm models, the study demonstrated that HT-KIT significantly reduces KIT expression, induces apoptosis in neoplastic human mast cells, and inhibits tumor growth. These findings indicate HT-KIT's potential as a targeted treatment for patients affected by various aggressive cancers associated with the KIT pathway. The results were shared on June 3, 2021, during a shareholder presentation.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a virtual information session on its pipeline product, HT-KIT, aimed at treating mast cell-derived cancers and anaphylaxis, set for June 3, 2021. Dr. Glenn Cruse will present positive preclinical results, indicating HT-KIT's efficacy in inducing apoptosis in neoplastic mast cells, leading to significant tumor reduction without noticeable toxicity in animal models. Hoth aims to address unmet medical needs, focusing on patient welfare and shareholder value.
On May 24, 2021, Hoth Therapeutics announced its participation as an exhibitor at the American Society of Clinical Oncology (ASCO) Annual Meeting, running from May 24th through July 6, 2021. The company focuses on developing treatments for rare cancers and discusses its HT-KIT and HT-001 therapeutics. HT-KIT targets cancers from aberrant KIT signaling, while HT-001 addresses skin toxicities from EGFR inhibitor therapy. CEO Robb Knie expressed excitement about contributing to oncology advancements.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) will host a virtual information session on May 18, 2021, at 11:00 AM ET, focusing on its pipeline product, HT-005 Z-Pods™, a novel endocannabinoid treatment for Cutaneous Lupus Erythematosus (CLE). Dr. Adam Friedman will discuss the treatment's potential, efficacy data from an animal study, and the unmet medical needs it addresses. The session aims to engage shareholders and interested parties. CEO Robb Knie emphasized the company's commitment to innovating therapies for patient needs and driving shareholder value.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced an expansion of its research agreement with Virginia Commonwealth University focused on developing the COVID-19 therapeutic HT-002. This decision comes after promising preclinical results from Dr. Michael Peters using live virus assays. The research will explore HT-002's effectiveness against SARS-CoV-2 variants, informed by recent molecular modeling studies. Hoth holds an exclusive license for this peptide therapeutic, which aims to provide new treatments for COVID-19.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced plans to develop its HT-KIT mRNA Frame Shifting Therapeutic targeting rare diseases affecting fewer than 200,000 people in the U.S., including various rare cancers such as aggressive systemic mastocytosis and acute myeloid leukemia. The company aims to secure Orphan Drug Designation (ODD) for HT-KIT, which offers extended market exclusivity and financial benefits during development. This strategic move aligns with Hoth's focus on improving treatment options for patients with unmet medical needs.